Biologics and Brews RSVP

YOU’RE INVITED:

Biologics and Brews

Take an evening to enjoy great food and brews with the biologics industry’s best.

Dive deeper into our expertise in biologics development—including mRNA and gene therapy production—at Biologics and Brews, our most popular networking event, now making its first exclusive UK stop.

Date: Wednesday, March 25, 2026
Time: 5-7 p.m.
Location: The Red Lion, Parliament Street–The Cabinet Room (48 Parliament St, London SW1A 2NH)

This happy hour during NextGen Biomed will feature food and brews while connecting you with thought leaders in advanced biologics production, including protein, enzymatic, mRNA, and gene-based therapies.

What’s on tap (besides the beer)?

Get ready to discuss all things drug development, including our Path to IND for biologics platform, designed to help biotech companies move from DNA to first-in-human Phase I clinical trials in as little as nine months.*

For a sneak peek at this offering, watch our recent webinar: “Accelerating biologics: From final DNA to Phase I in under 9 months.”

Originally presented at BIO 2025, this session explores the details of this innovative initiative, only offered by Thermo Fisher Scientific.

^{*Terms and Conditions: Titer levels provided are estimates based on third-party results and may vary depending on molecule type or other factors. Timelines from DNA to drug product and the start of clinical trials for all Path to IND for biologics options may vary depending on molecule type or other factors and are estimates to be finalized once third-party cell line development dates are available and confirmed. The 9-month timeline may incur additional risk.}

Please fill out the form to RSVP.

Meet our subject matter experts

For this happy hour only, we’re pleased to host two senior subject matter experts for a short presentation, followed by opportunities for 1:1 meetings:

Palak Patel

Senior Scientific and Technical Affairs Manager, Biologic Development and Manufacturing

Palak Patel is a scientific leader with more than 10 years of experience in early-phase biologic development. As a Senior Scientific and Technical Affairs Manager, she specializes in cell line and cell culture development for biologic drug substances, partnering with pharmaceutical companies to deliver innovative, phase-appropriate solutions that help speed up timelines.

Dr. TJ Chancellor

Senior Manager, Technical Program Design, Viral Vector and Advanced Therapies Services

Dr. T.J. Chancellor is a bioprocess development and manufacturing leader with more than 11 years of experience in biologics and gene therapy. As Senior Manager of Technical Program Design, he provides strategic and technical guidance to support viral vector and advanced therapy programs, helping clients advance efficiently toward clinical and commercial milestones.